腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的疗效及对血清MMP9、VEGF、HE4的影响

Curative effect of intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy on advanced ovarian cancer and its influences on serum MMP-9,VEGF and HE4

目的:探究腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的疗效及对血清基质金属蛋白酶(MMP)9、血管内皮生长因子(VEGF)、人附睾蛋白(HE4)的影响.方法:选取2015年3月至2017年3月我院肿瘤接收治64例晚期卵巢癌患者,按信封随机法将其分为对照组31例和观察组33例,对照组采取常规静脉化疗,观察组再对照基础上联合腹腔热灌注化疗,两组均治疗12周后,比较血清MMP-9、VEGF、HE4水平;同时随访36个月,比较两组远期疗效及复发率.结果:观察组总有效率、疾病控制率分别为63.64%、75.76%,均高于对照组的35.48%、51.16%,差异均有统计学意义(P<0.05);两组1年存活率比较,差异无统计学意义(P>0.05),观察组术后3年存活率为72.73%,高于对照组的48.39%,观察组复发率为27.27%,低于对照组的54.84%,差异均有统计学意义(P<0.05);治疗后两组血清MMP-9、VEGF、HE4水平均低于治疗前,观察组低于对照组,差异均有统计学意义(P<0.05).结论:腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌近期疗效切确,可显著降低患者血清清MMP-9、VEGF、HE4水平,降低复发率,改善远期生存.

Objective:To explore the curative effect of intraperitoneal hyperthermic perfusion chemotherapy(IHPC)combined with intravenous chemotherapy on advanced ovarian cancer and its influences on serum matrix metalloproteinases(MMP)9,vascular endothelial growth factor(VEGF)and human epididymal protein(HE4).Methods:A total of 64 patients with advanced ovarian cancer admitted to the hospital from March 2015 to March 2017 were enrolled.According to envelope method,they were divided into a control group(31 cases)and observation group(33 cases).The control group was given routine intravenous chemotherapy,while observation group was additionally given IHPC.After 12 weeks of treatment,levels of serum MMP-9,VEGF and HE4 were compared between the two groups.And then they were followed up for 36 months to compare long-term curative effect and recurrence rate of the two groups.Results:The total effective rate and disease control rate of the observation group were 63.64%and 75.76%respectively,which were higher than 35.48%and 51.16%of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).The 3-year survival rate in observation group was higher than that in control group(72.73%vs48.39%),while recurrence rate was lower than that in control group(27.27%vs54.84%)(P<0.05).After treatment,levels of serum MMP-9,VEGF and HE4 in both groups were decreased,which were lower in observation group than control group(P<0.05).Con clusi on:The short-term curative effect of IHPC combined with intravenous chemotherapy is significant on advanced ovarian cancer,which can significantly decrease levels of serum MMP-9,VEGF and HE4,reduce recurrence rate,and improve long-term survival.